BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic ... (ficant potential in atopicdermatitis the...)

BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis

Date:7/3/2009

ficant potential in atopic dermatitis therapy. Based on our results, ProtoCure(TM) emulsion cream holds great promises in the treatment of inflammatory skin disorders."

Atopic dermatitis is a chronic inflammatory disease of the skin with an onset typically already in infancy. It affects up to 20 per cent of the general population in the Western countries, and the prevalence rate is rising. Atopic dermatitis may significantly impair the quality of life of those affected. Existing treatments often have undesirable side effects and do not always meet the needs of patients.

BioCis Pharma Ltd. is a Karolinska Development portfolio company.

BioCis Pharma Ltd is an innovative drug development company developing drug therapies based on a novel, patented therapeutic principles that target unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The company's main investors are Karolinska Development AB (publ.), Finnish Industry Investment Ltd., and Etra Invest Ltd.

http://www.biocis.com

Contacts: Dr. Lasse Leino, CEO, BioCis Pharma Ltd., mobile phone +358-40-849-4694, lasse.leino@biocis.com

SOURCE BioCis Pharma Ltd
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
2. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
3. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
4. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
5. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
6. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
7. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
8. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
9. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
10. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
11. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD

Post Your Comments:

(Date:11/6/2009)...Newswire-FirstCall/ -- Oxygen Biotherapeutics, Inc...a previously approved reverse split of its common ...Monday, Nov. 9, 2009 on a 1-for-15 split-adjusted ...ade under the new symbol OXBT. The stock also will...lit becomes effective. ,, "This reverse split w...

(Date:11/6/2009)...swire/ -- Trius Therapeutics, Inc. announced today...m S-1 with the U.S. Securities and Exchange Commis...ffering of shares of its common stock. All shares ...l be offered by the Company. ,, Credit Suisse S... manager, Piper Jaffray & Co. is acting as co-...

(Date:11/6/2009)...PRNewswire-FirstCall/ -- Roper Industries, Inc. ... definitive agreement to acquire Verathon, Inc., a... The Verathon Board of Directors has approved the ...y regulatory approvals and closing conditions, inc...he closing to be completed in early December. ,...

Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2 Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3 Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2 Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3 ESC events in Asia tackle management of diabetes and cardiovascular disease 60408 1 ESC events in Asia tackle management of diabetes and cardiovascular disease 60408 2 ESC events in Asia tackle management of diabetes and cardiovascular disease 60408 3 GREENBioPharma Dec 2 3 2009 10591 1 Whooping Cough Immunity Lasts 30 Years or More 60406 1 Whooping Cough Immunity Lasts 30 Years or More 60406 2

[0] Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 [0] Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering [0] Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses

...armaceutical, Uppsala, Sweden, has been granted Or...) for the treatment of ovarian cancer. Orphan Drug... FDA to expedite and,optimize drug development and...granted. , (Logo: http://www.newscom.com/cgi-...gnation is intended to support the clinical develo...

...clics, Inc.,(Nasdaq: PCYC ) today announced that...escalation study to evaluate the safety and tolera... inhibitor of Bruton,s tyrosine kinase, or Btk,as ...r refractory B-cell,non-Hodgkin,s lymphoma (NHL). ...tested in humans, and is Pharmacyclics, fourth pro...

Other Medicine Technology:Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA 2 Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 2 Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 3 Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 4 Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma 5

Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkin's Lymphoma

(Date:11/6/2009)... CRME TSX: COM , VANCOUVER, Nov. 6 /PRNewswire-... / TSX: COM) today announced that it will report f...mber 30, 2009 on the morning of Monday, November 9...nd webcast at 9:00am Eastern (6:00am Pacific) on t...onference call, please dial 416-695-7806 or 888-78...

(Date:11/6/2009)...AINS, N.Y., Nov. 6 The Leukemia & Lymphom... Inc.,s Give & Get program, which in its first...ed more than $1 million to support LLS,s blood can...port services. ,, During the campaign, taking plac... downloadable 30% discount coupons participants...

(Date:11/6/2009)...ON, Nov. 6 The U.S. bishops sent an urgent messag... as House members steeped themselves in debate ove...re reform bill. ,, Moments before meeting to discu...lled for "a fair process" that would permit discus...eral law on abortion funding and conscience protec...

(Date:11/6/2009)...ton, VA)--Three leading scientific organizations s...ed a letter to President Obama today expressing th...nce concerning the use of personal protective equi...ected or confirmed cases of 2009 H1N1 influenza. ...a (SHEA), the Infectious Diseases Society of Ameri...

(Date:11/6/2009)... limitations seem to wane as years go by, research...) -- New research suggests that people with multip...f developing the disease are more likely to suffer...hers with the condition. , The findings, published...disease who relapse within five years of developin...

Breaking Medicine News(10 mins):Health News:Cardiome to Release Third Quarter Results 2 Health News:Cardiome to Release Third Quarter Results 3 Health News:Get a Jump on Your Holiday Shopping and Give Two Gifts This Season: One to Your Loved Ones and One to People Battling Blood Cancer 2 Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 2 Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 3 Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 4 Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 5 Health News:Prevention experts urge modification to 2009 H1N1 guidance for health care workers 2 Health News:Early Relapse of MS May Mean Fewer Issues Later 2

[1] Cardiome to Release Third Quarter Results [1] Get a Jump on Your Holiday Shopping and Give Two Gifts This Season: One to Your Loved Ones and One to People Battling Blood Cancer [0] Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable [0] Prevention experts urge modification to 2009 H1N1 guidance for health care workers [1] Early Relapse of MS May Mean Fewer Issues Later

...ters has received the first annual Vision Award fo...ted process to dramatically increase the processin...a. , Irvine, CA (Vocus) O... improvement programs by doing just that. LifeMa...

...Prof. Weihong Song, who is also the Jack Brown and... at UBC, found that if Valproic Acid (VPA) is used...it is reversed. , The study, published in the Jou...In doing so, plaque formation is discontinued. Amy...

...ates Multiple Password Problem With,Single Sign-On...linical and Business Appli...System, one of,the largest healthcare systems in A...up and running with single sign-on (SSO),and conte...

...T -- UCB announced,today the company has joined th...ucation Foundation (REF) as a Pinnacle sponsor of ... Rheumatoid Arthritis." The,announcement was made ... disease can be eradicated and this will happen on...

...ious atrial fibrillation, review finds, , ...bone-building medications known as bisphosphonates.... , A review of available research concludes that ... strokes. , "In addition to possible gastrointesti...

...Corporation,(Nasdaq: HLTH ) announced today that ...o 80,000,000 shares of its common stock at a price... to be purchased in the tender offer,represents ap...t on October 24, 2008 was $8.06 per share., The t...

Other Medicine News:Health News:LifeMasters Receives 2008 Vision Award for Business Impact 2 Health News:LifeMasters Receives 2008 Vision Award for Business Impact 3 Health News:Baptist Health System Deploys Sentillion's Vergence Solution to Provide Secure Identity and Access Management to 3,000 Clinicians 2 Health News:Baptist Health System Deploys Sentillion's Vergence Solution to Provide Secure Identity and Access Management to 3,000 Clinicians 3 Health News:UCB Becomes Pinnacle Donor to the American College of Rheumatology Research and Education Foundation's Research Campaign 2 Health News:UCB Becomes Pinnacle Donor to the American College of Rheumatology Research and Education Foundation's Research Campaign 3 Health News:Osteoporosis Meds Linked to Heart Problem 2 Health News:Osteoporosis Meds Linked to Heart Problem 3 Health News:HLTH Corporation Announces Commencement of Its Tender Offer 2 Health News:HLTH Corporation Announces Commencement of Its Tender Offer 3 Health News:HLTH Corporation Announces Commencement of Its Tender Offer 4

LifeMasters Receives 2008 Vision Award for Business Impact Common epilepsy drug could prevent and treat Alzheimer's disease Baptist Health System Deploys Sentillion's Vergence Solution to Provide Secure Identity and Access Management to 3,000 Clinicians UCB Becomes Pinnacle Donor to the American College of Rheumatology Research and Education Foundation's Research Campaign Osteoporosis Meds Linked to Heart Problem HLTH Corporation Announces Commencement of Its Tender Offer

LB Agarose Plates

LB Top Agarose 100ml Bottle

LB Agar (Bottle)

LB Broth with 7.5% Glycerol

Medicine Products:

LB Agarose Plates LB Top Agarose 100ml Bottle LB Agar (Bottle)LB Broth with 7.5% Glycerol

BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic ...(ficant potential in atopicdermatitis the...),Health